Sernova Biotherapeutics Q4 2025 Earnings Report

Sernova Biotherapeutics EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Sernova Biotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sernova Biotherapeutics Announcement Details

• Quarter: Q4 2025
• Date: 12/19/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Sernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation. Beyond diabetes, the company is exploring broader applications of its delivery platform, including therapies for hemophilia and other endocrine and metabolic disorders. Preclinical studies have demonstrated the ability of the Cell Pouch to promote cell engraftment and function, positioning Sernova’s technology as a potential alternative to conventional chronic drug administration.

Founded in 2008 and formerly known as Sernova Corp, the company rebranded as Sernova Biotherapeutics in late 2023 to better reflect its evolving pipeline. Sernova conducts its clinical activities across North America and Europe, collaborating with academic and clinical research centers to advance its trials. Leading the organization is Dr. Philip A. Toleikis, Sernova’s founder, president and chief executive officer, who brings more than two decades of experience in regenerative medicine and cell‐based therapy development.